3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
7
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Breast Diseases
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
36
Bevacizumab
25
Cyclophosphamide
22
Blood Specimen Collection
18
Nivolumab
17
Carboplatin
15
Standard of Care
14
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
11
Fluorouracil
11
Doxorubicin
11
Cisplatin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Biopsy
8
130-nm albumin-bound paclitaxel
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Gonadotropin-Releasing Hormone
×
90 days
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled